Prosecution Insights
Last updated: November 20, 2026
Application No. 18/956,159

DEVICES AND METHODS FOR REDUCING CYSTINE CRYSTALS IN VIVO

Non-Final OA §102§103§112
Filed
Nov 22, 2024
Priority
Sep 22, 2017 — provisional 62/561,788 +3 more
Examiner
ALAM, AYAAN A
Art Unit
1611
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University of Florida Research Foundation Inc.
OA Round
1 (Non-Final)
39%
Grant Probability
At Risk
1-2
OA Rounds
1y 3m
Est. Remaining
75%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allowance Rate
59 granted / 153 resolved
-21.4% vs TC avg
Strong +37% interview lift
Without
With
+36.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
53 currently pending
Career history
222
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
54.1%
+14.1% vs TC avg
§102
11.1%
-28.9% vs TC avg
§112
22.1%
-17.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 153 resolved cases

Office Action

§102 §103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Applicant’s election without traverse of claims 1-18 in the reply filed on 09/25/2026 is acknowledged. Claims 1-18 are currently under examination and the subject of the present Office Action. Claims 19-20 are withdrawn from consideration without traverse. As such, the restriction is made final. Information Disclosure Statement The information disclosure statement (IDS) filed on 11/22/2024 has been considered here. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 4 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 4 recites the limitation "the cystine-sequestering material" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim. For purposes of search and consideration, the claim is understood to read “the gold nanoparticles are…” instead of “the cystine-sequestering material is”. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 1, 3-6, 8, 10, 13-15, and 18 are rejected under 35 U.S.C. 102(a)(1) and (a)(2) as being anticipated by US PGPUB 20130235335 A1 (Forrest, 2013; as submitted on IDS of 11/22/2024). In regard to claims 1, 3, 8, 10, 13, and 15 Forrest teaches a contact lens comprised of silicone hydrogel lenses (see Forrest, paragraph 0010) and gold nanoparticles (i.e. a cystine-sequestering material) (see Forrest, paragraph 0012). The gold nanoparticles are incorporated into the contact lens (i.e., trapped) (see Forrest, paragraph 0013) by having the lenses or the lens material exposed to a nanoparticle solution via soaking (see Forrest, paragraph 0053-54). In regard to claims 1, 4, and 14 Forrest teaches that the lenses were soaked in at least two solutions, one at 1% and another at 10% of gold nanoparticle solution (see Forrest, paragraph 0080). This overlaps with the amount of gold nanoparticles used in the instant specification (see instant specification as filed, page 14, paragraph 1) and as such would be an amount effective to uptake cystine from the eye of a patient in the amounts as claimed. In regard to claims 5-6, the gold nanoparticles are taught to have a diameter of 20 nm in an example (see Forrest, paragraphs 0046-0049). Further, in regard to claim 13, as the teachings of Forrest would yield an identical contact lens as instantly claimed, the properties, such as the sequestering of cystine within the lens would be present since physical properties are not separable from the products themselves. In regards to claim 18, the claim limitation is a future intended use, however the future intended use of a product is not considered to contribute to the overall patentability of the instant invention, particularly when the product itself is claimed and that same product is taught in the prior art. Claims 1, 3-5, 8, 10, 13, 15, and 18 are rejected under 35 U.S.C. 102(a)(1) and (a)(2) as being anticipated by US PGPUB 20150190279 A1 (Acharya, 2015; as submitted on IDS of 11/22/2026). In regard to claims 1, 3-5, 8, 10, 13, and 15, Acharya teaches an intra-ocular device (see Acharya, paragraph 0039) such as contact lenses (see Acharya, paragraph 0118), comprising gold nanoparticles (60 nm diameter) (see paragraph 0096). Further, the device is used to treat cystinosis (see Acharya, paragraph 0045). The device was used to remove 90% of cystine in 27 days in the eyes of a patient with cystinosis (see Acharya, paragraph 0189). One with ordinary skill in the art would understand that the removal of 90% of cystine from the eyes of the patient means that the amount of gold nanoparticles used are in an amount effective to uptake cystine from the eye of a patient. Further, in regard to claim 13, as the teachings of Acharya would yield an identical contact lens as instantly claimed, the properties, such as the sequestering of cystine within the lens would be present since physical properties are not separable from the products themselves. In regards to claim 18, the claim limitation is a future intended use, however the future intended use of a product is not considered to contribute to the overall patentability of the instant invention, particularly when the product itself is claimed and that same product is taught in the prior art. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claims 1, 3-5, 8, 10, 13, and 15-18 are rejected under 35 U.S.C. 103 as being unpatentable over US PGPUB 20150190279 A1 (Acharya, 2015; as submitted on IDS of 11/22/2026). The teachings of Acharya have been described supra. Further in regard to claim 3, Acharya teaches an intra-ocular device, such as contact lenses (see Acharya, paragraph 0118) or fornix inserts (see Acharya, paragraph 0045), comprising gold nanoparticles (see paragraph 0096). Further in regard to claims 10 and 15, the contact lens is taught to have a hydrogel matrix (see Acharya, paragraphs 0119-0120) comprising polyHEMA (i.e. a combination of HEMA as claimed) (see Acharya, paragraph 0121 and 0154) with gold nanospheres incorporated into the lens (see Acharya, paragraph 0096). In regard to claims 16-17, the contact lens is taught to comprise cysteamine (see Acharya, paragraph 0045; Example 15). Further, in regards to claim 17, as the teachings of Acharya would yield an identical contact lens as instantly claimed, the properties, such as the diffusion of the cysteamine would be present since physical properties are not separable from the products themselves. Claim 17 further claims a future intended use, however the future intended use of a product is not considered to contribute to the overall patentability of the instant invention, particularly when the product itself is claimed and that same product is taught in the prior art. Acharya does not teach with sufficient specificity to anticipate and so the claims are obvious. It would be obvious to one with ordinary skill in the art before the effective filing date to rearrange the teachings of Acharya with a reasonable expectation of success to obtain the intra-ocular device of the instant claims. A reference is analyzed using its broadest teachings. MPEP 2123 [R-5]. “[W]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious”. KSR v. Teleflex, 127 S,Ct. 1727, 1740 (2007)(quoting Sakraida v. A.G. Pro, 425 U.S. 273, 282 (1976). “[W]hen the question is whether a patent claiming the combination of elements of prior art is obvious”, the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR v. Teleflex, 127 S.Ct. 1727, 1741 (2007). The Court emphasized that “[a] person of ordinary skill is… a person of ordinary creativity, not an automaton.” Id. at 1742. A person of ordinary skill in the art who is not an automaton is capable of producing the intra-ocular device of the instant claims with predictable results. Claims 1, 3-6, 8, 10-15, and 18 are rejected under 35 U.S.C. 103 as being unpatentable over US PGPUB 20130235335 A1 (Forrest, 2013; as submitted on IDS of 11/25/2026). The teachings of Forrest have been described supra. In regard to claims 11-12, Forrest teaches that the method of making the contact lens may or may not change the color or tint of the lens (i.e., the lens can be colorless), saying specifically that altering the optical density may include tinting the contact lenses, although the optical density can be altered without changing the color (see Forrest, paragraphs 0041, 0044, 0051-0052). Forrest does not teach with sufficient specificity to anticipate and so the claims are obvious. It would be obvious to one with ordinary skill in the art before the effective filing date to rearrange the teachings of Forrest with a reasonable expectation of success to obtain the method of the instant claims. A reference is analyzed using its broadest teachings. MPEP 2123 [R-5]. “[W]hen a patent simply arranges old elements with each performing the same function it had been known to perform and yields no more than one would expect from such an arrangement, the combination is obvious”. KSR v. Teleflex, 127 S,Ct. 1727, 1740 (2007)(quoting Sakraida v. A.G. Pro, 425 U.S. 273, 282 (1976). “[W]hen the question is whether a patent claiming the combination of elements of prior art is obvious”, the relevant question is “whether the improvement is more than the predictable use of prior art elements according to their established functions.” (Id.). Addressing the issue of obviousness, the Supreme Court noted that the analysis under 35 USC 103 “need not seek out precise teachings directed to the specific subject matter of the challenged claim, for a court can take account of the inferences and creative steps that a person of ordinary skill in the art would employ.” KSR v. Teleflex, 127 S.Ct. 1727, 1741 (2007). The Court emphasized that “[a] person of ordinary skill is… a person of ordinary creativity, not an automaton.” Id. at 1742. A person of ordinary skill in the art who is not an automaton is capable of producing the method of the instant claims with predictable results. Claims 1, 3-6, 8, and 10-18 are rejected under 35 U.S.C. 103 as being unpatentable over US PGPUB 20130235335 A1 (Forrest, 2013; as submitted on IDS of 11/25/2026) in view of US PGPUB 20150190279 A1 (Acharya, 2015; as submitted on IDS of 11/22/2026). The teachings of Forrest have been described supra. The teachings of Forrest are silent on the use of cysteamine. The teachings of Acharya have been described supra. In regard to claims 1, 3-6, 8, and 10-18, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of Forrest and Acharya to formulate the composition as claimed as both references teach the use of gold nanoparticles in contact lenses for the same use. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose .... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). It would be obvious to one with ordinary skill in the art to combine the teachings of Forrest with the teachings of Acharya according to the known method of making a contact lens for the use of drug treatment using gold nanoparticles (see Forrest, claims 14-20) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results. Claims 2, 7, and 9 are rejected under 35 U.S.C. 103 as being unpatentable over US PGPUB 20130235335 A1 (Forrest, 2013; as submitted on IDS of 11/25/2026) in view of US PGPUB 20150190279 A1 (Acharya, 2015; as submitted on IDS of 11/22/2026) as applied to claims 1, 3-6, 8, and 10-18 above, and further in view of JP 2001011109 A (Takuma, 2001; machine translation provided by PE2E via FIT). The teachings of Forrest and Acharya have been described supra. The teachings of Forrest and Acharya are silent on the use of thiolated acrylates. Takuma teaches an optical lens (see abstract) comprising known polymerizable compounds such as polythiourethane acrylates (i.e., thiolated acrylates) (see Takuma, page 6, paragraph 3-4 and page 7, paragraph 2). In regard to claims 2, 7, and 9, it would have been prima facie obvious to a person of ordinary skill in the art, before the effective filing date of the claimed invention, to combine the teachings of Forrest and Acharya with Takuma to formulate the composition as claimed as all three references are drawn to using polymerizable compounds in optical lenses. "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose .... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980). It would be obvious to one with ordinary skill in the art to combine the teachings of Forrest and Acharya with the teachings of Takuma according to the known method of making a contact lens for the use of drug treatment using gold nanoparticles (see Forrest, claims 14-20) to yield predictable results with a reasonable expectation of success. One with ordinary skill in the art would be motivated to combine prior art elements according to known methods to yield predictable results. Further, as the combination of teachings of Forrest, Acharya, and Takuma would yield an identical composition as instantly claimed, the properties, such as the thiolated acrylate sequestering the cysteine, of the composition would be the same. "Products of identical chemical composition can not have mutually exclusive properties." In re Spada, 911 F.2d 705, 709, 15 USPQ2d 1655, 1658. As the prior art teaches an identical chemical structure, the properties applicant discloses and/or claims are necessarily present. Conclusion No claims allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to AYAAN A ALAM whose telephone number is (571)270-1213. The examiner can normally be reached M-F 8-5 EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Bethany Barham can be reached at 571-272-6175. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /ISIS A GHALI/Primary Examiner, Art Unit 1611 /A.A.A./Examiner, Art Unit 1611
Read full office action

Prosecution Timeline

Nov 22, 2024
Application Filed
Nov 02, 2026
Non-Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12799336
SURFACE-TREATED METAL OXIDE PARTICLES, DISPERSION LIQUID, COSMETIC AND METHOD FOR PRODUCING SURFACE-TREATED METAL OXIDE PARTICLES
4y 1m to grant Granted Nov 17, 2026
Patent 12746256
TOPICAL COMPOSITION FOR TREATMENT OF PAIN AND SYMPTOMS ASSOCIATED WITH RHINOSINUSITIS, METHOD OF MAKING, AND METHOD OF USE
5y 3m to grant Granted Sep 29, 2026
Patent 12745777
FERRATE COMPOSITIONS FOR SURFACE DISINFECTION
3y 9m to grant Granted Sep 29, 2026
Patent 12714098
AGROCHEMICAL ELECTROLYTE COMPOSITIONS
6y 8m to grant Granted Aug 25, 2026
Patent 12702643
Ion-Exchange Composition With Water-Soluble Mucoadhesive Polymers
6y 10m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
39%
Grant Probability
75%
With Interview (+36.7%)
3y 3m (~1y 3m remaining)
Median Time to Grant
Low
PTA Risk
Based on 153 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month